In the recent past, the introduction of glucagon-like peptide 1 receptor agonist (GLP1-RA), a group of anti-hyperglycaemic agents, which work on the incretin axis and improve insulin secretion while lowering glucagon secretion from the pancreas in the therapeutic armamentarium of T2D, has resulted in improved cardiovascular outcomes along with improved metabolic control and significant weight reduction4. The gene discussed is INS; the disease is type 2 diabetes mellitus.